Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

Millions of people who bought DNA tests from genetic testing service 23andme have been urged to delete their personal data ...

D NA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire board of directors resigned over disagreements with the C ...

The news comes as Pfizer is trying to catch up with U.K.-based GlaxoSmithKline (GSK). Its RSV vaccine for adults was approved by the FDA in May. The company is already undergoing priority review with ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious ...

Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...

GSK, Sanofi and CSL Ltd have secured $72 million from the US government to ramp up production of bird flu vaccines, Reuters ...

ViiV’s strategy for CAB LA for PrEP in L&MICs is to maximise rapid access and uptake for populations with highest unmet needs ...

Mpox – formerly known as monkeypox – is rapidly spreading in several African countries, prompting the World Health ...

The mRNA-based supplier of vaccines profited from Covid-19 vaccine sales. As the years passed, Covid evolved. The weaker ...

The idea is that if you move your focus to attracting people, you’ll ultimately attract the companies: If you build it (the ...